Biocept, Inc.
BIOCQ
$0.00
$0.000.00%
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -89.88% | -96.63% | -106.53% | -94.24% | -51.70% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -89.88% | -96.63% | -106.53% | -94.24% | -51.70% |
| Cost of Revenue | -68.22% | -70.70% | -57.05% | -48.73% | 7.52% |
| Gross Profit | 11.03% | -124.50% | -232.34% | -176.86% | -148.07% |
| SG&A Expenses | -37.14% | -62.65% | -36.17% | -26.23% | 14.63% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -57.33% | -64.83% | -47.02% | -38.05% | 13.87% |
| Operating Income | 38.17% | -230.29% | -252.63% | -1,746.73% | -465.73% |
| Income Before Tax | 63.85% | -223.26% | -245.50% | -1,520.00% | -449.45% |
| Income Tax Expenses | -- | -- | -200.00% | -- | -- |
| Earnings from Continuing Operations | 63.85% | -223.26% | -226.76% | -1,520.00% | -449.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 63.85% | -223.26% | -226.76% | -1,520.00% | -449.45% |
| EBIT | 38.17% | -230.29% | -252.63% | -1,746.73% | -465.73% |
| EBITDA | 40.98% | -280.22% | -301.68% | -5,346.93% | -575.98% |
| EPS Basic | 80.35% | -209.12% | -222.38% | -1,366.17% | -337.53% |
| Normalized Basic EPS | 80.35% | -209.12% | -240.88% | -1,366.27% | -337.53% |
| EPS Diluted | 80.35% | -212.60% | -222.51% | -1,376.86% | -324.37% |
| Normalized Diluted EPS | 80.35% | -209.12% | -240.88% | -1,366.27% | -337.53% |
| Average Basic Shares Outstanding | 83.94% | 4.58% | 1.35% | 10.49% | 25.59% |
| Average Diluted Shares Outstanding | 83.94% | 4.58% | 1.35% | 10.49% | 25.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |